Under the terms of this agreement, the partners will jointly work to discover and develop new ways of treating respiratory diseases, in particular severe asthma and chronic obstructive pulmonary disease (COPD), as well as immuno-allergic diseases.
For each research theme, Johns Hopkins ACI and Sanofi-Aventis will work on new target identification, assay development and compound screening. The two research organizations will also collaborate on the design of potential clinical studies and the selection of biomarkers.
Marc Cluzel, senior vice president of R&D at Sanofi-Aventis, said: “This collaboration will allow Sanofi-Aventis and Johns Hopkins allergy and clinical immunology to join their efforts to identify new therapeutic approaches, in particular in severe asthma and COPD. We are looking forward to working with Johns Hopkins on this endeavor.”